Biohaven (BHVN) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zymeworks (ZYME) has outperformed Biohaven (BHVN) over the past year, gaining 60.8% versus a loss of 20.9%. Zymeworks is the larger company by market cap ($1.90 billion vs $1.79 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | ZYME |
|---|---|---|
| Share price | $11.88 | $26.53 |
| Market cap | $1.79B | $1.90B |
| 1-day change | -1.66% | +3.43% |
| YTD return | +5.23% | +0.76% |
| 1-year return | -20.91% | +60.79% |
| 5-year return | — | +2.27% |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $-4.56 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.57 | $31.34 |
| 52-week low | $7.48 | $16.00 |
| Distance from 52-week high | -36.01% | -15.35% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +79.04% | +55.33% |
| Average volume | 2.61M | 687.87K |
| Shares outstanding | 151.04M | 71.20M |
| Employees | 274 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed BHVN by 81.7 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
BHVN vs ZYME FAQ
Which is bigger, Biohaven or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.90B compared with $1.79B for Biohaven (BHVN).
Which stock has performed better over the past year, BHVN or ZYME?
ZYME returned +60.79% over the past 12 months, compared with -20.91% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.